Integrated Diagnostics Holdings plc (FRA:8I8)
Germany · Delayed Price · Currency is EUR | Market Cap | 273.09M +16.6% |
| Revenue (ttm) | 163.35M +35.5% |
| Net Income | 27.30M +39.5% |
| EPS | 0.05 +40.2% |
| Shares Out | n/a |
| PE Ratio | 10.00 |
| Forward PE | n/a |
| Dividend | 0.02 (5.07%) |
| Ex-Dividend Date | May 28, 2026 |
| Volume | n/a |
| Open | 0.4280 |
| Previous Close | 0.4260 |
| Day's Range | 0.4280 - 0.4300 |
| 52-Week Range | 0.3580 - 0.7100 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 11, 2026 |
About FRA:8I8
Integrated Diagnostics Holdings plc, a consumer healthcare company, provides medical diagnostics services to patients. It offers approximately 3,000 diagnostic pathology tests, such as immunology, microbiology, haematology, endocrinology, clinical chemistry, molecular biology, parasitology, histopathology, and genetics. The company also provides radiology services, such as positron emission tomography - computed tomography (PET-CT), MRI, computed tomography (CT), mammography, ultrasound, X-Ray, electromyography, electroencephalography, electroe... [Read more]
Financial Performance
In 2025, FRA:8I8's revenue was 7.86 billion, an increase of 37.34% compared to the previous year's 5.72 billion. Earnings were 1.26 billion, an increase of 17.15%.
Financial numbers in EGP Financial StatementsNews
Integrated Diagnostics Holdings Earnings Call Transcript: H1 2026
Revenue grew 37% year-on-year in H1 2026, with strong profitability and margin improvement across all markets. Egypt led growth, while Saudi Arabia and Nigeria showed significant operational progress. No interim dividend is planned, and expansion will continue, especially in Egypt and Saudi Arabia.
Integrated Diagnostics Holdings Quarterly report: H1 2026
Integrated Diagnostics Holdings has published its H1 2026 quarterly earnings report on September 15, 2026.
Integrated Diagnostics Holdings Earnings Call Transcript: Q1 2026
Q1 2026 saw 31% revenue growth and 78% net profit increase, driven by strong performance in Egypt, rapid expansion in Saudi Arabia, and improved margins in Nigeria. Management remains vigilant on regional risks and maintains flexibility on pricing and expansion plans.
Integrated Diagnostics Holdings Earnings release: Q1 2026
Integrated Diagnostics Holdings released its Q1 2026 earnings on June 1, 2026, summarizing the period's financial results.
Integrated Diagnostics Holdings Slides: Q1 2026
Integrated Diagnostics Holdings has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on June 1, 2026.
Integrated Diagnostics Holdings Earnings Call Transcript: H2 2025
2025 saw 37% revenue growth, margin expansion, and strong performance in Egypt, Nigeria, and Saudi Arabia. 2026 guidance targets 25% sales growth, 200 new branches, and continued investment, with risks from regional geopolitics and currency volatility.
Integrated Diagnostics Holdings Annual report: H2 2025
Integrated Diagnostics Holdings has published its H2 2025 annual report on April 21, 2026.
Integrated Diagnostics Holdings Annual report: H2 2025
Integrated Diagnostics Holdings has published its H2 2025 annual report on April 21, 2026.
Integrated Diagnostics Holdings Slides: H2 2025
Integrated Diagnostics Holdings has posted slides in relation to its H2 2025 quarterly earnings report, which was published on April 21, 2026.
Integrated Diagnostics Holdings Earnings Call Transcript: Q3 2025
Strong nine-month 2025 results featured 41% revenue growth, margin expansion, and robust performance in Egypt, Jordan, Nigeria, and Saudi Arabia. Guidance for 2025 remains above 35% revenue growth and 30%+ EBITDA margin, with continued network expansion and cost discipline.
Integrated Diagnostics Holdings Earnings release: Q3 2025
Integrated Diagnostics Holdings released its Q3 2025 earnings on November 25, 2025, summarizing the period's financial results.
Integrated Diagnostics Holdings Slides: Q3 2025
Integrated Diagnostics Holdings has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 25, 2025.